89446-52-6

Upstream product

• 89446-51-5 7-bromo-4-methyl-1,2-dihydroquinolin-2-one 
• 61579-06-4 N-(3-bromo-phenyl)-3-oxo-butyramide 
• 89446-51-5 7-bromo-4-methyl-quinolin-2-ol 

Downstream Products

• 246542-48-3 4-(7-bromo-4-methyl-quinolin-2-yloxy)-benzonitrile 
• 246542-79-0 4-[(7-bromo-4-methyl-quinolin-2-yl)-amino]-benzonitrile 
• 121269-20-3 (Z)-2-(4-Methyl-2-morpholin-4-yl-quinolin-7-ylmethyl)-3-phenylamino-acrylonitrile 
• 89446-55-9 2-<(2-methoxy-4-methyl-7-quinolyl)methyl>-3-anilinoacrylonitrile 
• 653592-13-3 (E)-3-[2-(4-Cyano-phenoxy)-4-methyl-quinolin-7-yl]-but-2-enoic acid ethyl ester 
• 246542-80-3 4-{[7-(2-methyl-phenyl)-4-methyl-quinolin-2-yl]-amino}-benzonitrile 
• 246542-49-4 4-(4-methyl-7-p-tolyl-quinolin-2-yloxy)-benzonitrile 
• 653592-08-6 4-(4-methyl-7-o-tolyl-quinolin-2-yloxy)-benzonitrile 
• 246542-89-2 4-[(7-allyl-4-methyl-quinolin-2-yl)-oxy]-benzonitrile 

Relevant academic research and scientific papers

Discovery of a novel class of triazolones as Checkpoint Kinase inhibitors - Hit to lead exploration

Checkpoint Kinase-1 (Chk1, CHK1, CHEK1) is a Ser/Thr protein kinase that mediates cellular responses to DNA-damage. A novel class of Chk1 inhibitors, triazoloquinolones/triazolones (TZ's) was identified by high throughput screening. The optimization of th

Antithrombotic quinoxazolines

Quinoxazolines having antithrombotic activity. Exemplary of those disclosed are: 4-{[6-(N-carboxymethyl-quinolin-8-yl-sulphonylamino)-1-methyl-2-oxo-1,2-dihydroquinoxalin-3-yl]-methyl}-benzamidine, 4-{[6-(1-(N-cyclopentyl-carboxymethylcarbonylamino)-cyclo-propyl)-1-methyl-2-oxo-1,2-dihydroquinoxalin-3-yl]-methyl}-benzamidine, and 4-{[7-(N-carboxymethylaminocarbonyl-ethylamino)-4-methyl-quinolin-2-yl]-oxo}-benzamidine.

2,4-Diamino-5-benzyloxypyrimidines and Analogues as Antibacterial Agents. 11. Quinolylmethyl Analogues with Basic Substituents Conveying Specificity

A series of nine 2,4-diamino-5-pyrimidines has been prepared by condensations of quinolinecarboxaldehydes with β-anilinopropionitriles, followed by treatment with guanidine.All compounds had basic or methoxy substituents at the 2-

2,4-diamino-5-(1,2,3,4-tetrahydro-(substituted or unsubstituted)-6-quinolylmethyl)pyrimidines, useful as antimicrobials

Compounds of the formula (II) STR1 or a salt, N-oxide or acyl derivative thereof, wherein Y is a group STR2 which is optionaly substituted and which optionally contain a nitrogen atom at one of positions A, B, C, D or E, in which the dotted line represents aromatic rings unless one of the rings contains a nitrogen atom in which case this ring is either aromatic or partially saturated, have antimicrobial properties. Processes for making these compounds, pharmaceutical compositions containing them and the medical use of the compounds are also disclosed.